Printed from Voxsanity (voxsanity.com.au) — NCT07690332 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Ovarian Cancer Trial, Not Yet Recruiting
NCT07690332
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The patient must be female and aged 18 years or older.
- The patient must have a laboratory-confirmed diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- The patient's cancer must have gotten worse during or after their most recent cancer treatment.
- The patient's tumor must show a certain level of a protein called folate receptor alpha (FRα), confirmed by a specific test (VENTANA FOLR1), with at least 25% of tumor cells showing a strong enough reaction.
- The patient must have normal major organ function and be considered suitable for the study treatment (either alone or in combination with another drug) based on clinical assessment.
- The patient must have at least one measurable area of cancer that can be assessed using standard imaging guidelines (RECIST v1.1).
- The patient must have an activity and health status score of 0, 1, or 2 on a standard scale used by doctors to assess daily functioning (ECOG Performance Status).
- Any side effects from previous cancer treatments (except hair loss) must have mostly resolved to a mild level or lower before joining the trial.
- If the patient has had major surgery, it must have been completed at least 4 weeks before starting the study treatment, and the patient must have recovered or stabilised from any post-surgery complications.
- The patient must be expected to survive for at least 12 weeks, as assessed by the treating doctor.
- The patient must be willing and able to sign a consent form and follow all study requirements, including scheduled treatments, regular check-ups, and follow-up visits.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are currently participating in another clinical study at the same time.
- People who have had a known serious allergic reaction to monoclonal antibody therapies, a type of drug called maytansinoids, or to the study drug or any of its ingredients.
- People who have active or ongoing corneal (eye surface) disorders, a history of corneal transplant, or certain eye conditions that require ongoing treatment or monitoring — such as uncontrolled glaucoma, wet age-related macular degeneration requiring injections into the eye, active diabetic eye disease affecting the central vision, macular degeneration, swelling of the optic nerve, or vision in only one eye.
- People who have previously been treated with the study drug (MIRV) or other treatments that target the FRα protein — this applies to patients in the prospective (forward-looking) part of the study only.
- People who are pregnant or breastfeeding; women who could become pregnant must agree to use highly effective contraception while taking the study drug and for at least 7 months after the last dose.
- People who are currently taking part in any other interventional study (a study involving an active treatment or procedure) beyond standard clinical care.
- People who have any other condition that the treating doctor believes would make participation in this study unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
NING LI-GYN
Registry
ClinicalTrials.gov
Start date
20 July 2026
Est. completion
30 September 2028
Primary endpoints
Incidence of grade ≥ 3 treatment-related adverse events (TRAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.